Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07575412CT.gov SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | — | Not Yet Recruiting | — | — | — |
NCT07562568CT.gov SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | — | Not Yet Recruiting | — | — | — |
NCT06454409CT.gov Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Suspended | — | — | — |
NCT05766514CT.gov Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | — | Withdrawn | — | — | — |
NCT06548230CT.gov A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | — | Recruiting | — | — | — |
NCT06778187CT.gov Oral-ATO for TP53-mutated Myeloid Malignancies | — | Recruiting | — | — | — |
NCT06616636CT.gov A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | — | Recruiting | — | — | — |
NCT06498973CT.gov Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant | — | Recruiting | — | — | — |
NCT05367401CT.gov A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants | — | Withdrawn | — | — | — |
NCT06656494CT.gov ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies | — | Recruiting | — | — | — |
Show 126 more trialsShow fewer
NCT05823480CT.gov Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS | — | Withdrawn | — | — | — |
NCT05564390CT.gov MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | — | Recruiting | — | — | — |
NCT06419634CT.gov Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT05883956CT.gov A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT06008405CT.gov Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy | — | Unknown | — | — | — |
NCT05292664CT.gov Venetoclax Basket Trial for High Risk Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05641259CT.gov A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML | — | Unknown | — | — | — |
NCT05246384CT.gov Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT05829226CT.gov A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT05226455CT.gov Venetoclax in Patients With MDS or AML in Relapse After AHSCT | — | Active Not Recruiting | — | — | — |
NCT05788679CT.gov A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | — | Recruiting | — | — | — |
NCT05476770CT.gov Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05428969CT.gov A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies | — | Active Not Recruiting | — | — | — |
NCT05107856CT.gov PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | — | Terminated | — | — | — |
NCT05275439CT.gov Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | — | Terminated | — | — | — |
NCT04988555CT.gov A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | — | Recruiting | — | — | — |
NCT05823714CT.gov Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT | — | Unknown | — | — | — |
NCT05168202CT.gov A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes | — | Terminated | — | — | — |
NCT04937166CT.gov A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies | — | Terminated | — | — | — |
NCT05140811CT.gov A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | — | Unknown | — | — | — |
NCT04912063CT.gov Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome | — | Terminated | — | — | — |
NCT04771130CT.gov A Study of BGB-11417 in Participants With Myeloid Malignancies | — | Recruiting | — | — | — |
NCT04842604CT.gov Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML | — | Completed | — | — | — |
NCT05175508CT.gov Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | — | Unknown | — | — | — |
NCT05048498CT.gov Pharmacokinetics, Tolerability and Safety of NEX-18a | — | Completed | — | — | — |
NCT04730258CT.gov A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML | — | Active Not Recruiting | — | — | — |
NCT04752163CT.gov DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT04712942CT.gov Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | — | Completed | — | — | — |
NCT04358393CT.gov A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | — | Unknown | — | — | — |
NCT04609826CT.gov A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT04603001CT.gov Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | — | Active Not Recruiting | — | — | — |
NCT04581512CT.gov Study to Evaluate the Safety and Tolerability of EP0042 | — | Recruiting | — | — | — |
NCT04146038CT.gov Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | — | Completed | — | — | — |
NCT04227847CT.gov A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | — | Recruiting | — | — | — |
NCT04487106CT.gov Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT04275518CT.gov A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | — | Recruiting | — | — | — |
NCT04256317CT.gov A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | — | Recruiting | — | — | — |
NCT04243785CT.gov A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT04296214CT.gov Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT06550713CT.gov A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies | — | Recruiting | — | — | — |
NCT04022785CT.gov PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT04061239CT.gov Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML | — | Recruiting | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT03814005CT.gov A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems | — | Completed | — | — | — |
NCT04173533CT.gov Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT | — | Unknown | — | — | — |
NCT03813147CT.gov Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT03843528CT.gov Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | — | Active Not Recruiting | — | — | — |
NCT03862157CT.gov Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03612739CT.gov EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 | — | Withdrawn | — | — | — |
NCT03613532CT.gov Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | — | Active Not Recruiting | — | — | — |
NCT03683433CT.gov Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | — | Recruiting | — | — | — |
NCT03588078CT.gov Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | — | Unknown | — | — | — |
NCT03465540CT.gov Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | — | Terminated | — | — | — |
NCT03493646CT.gov Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | — | Completed | — | — | — |
NCT03471260CT.gov Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | — | Recruiting | — | — | — |
NCT03397173CT.gov TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid | — | Completed | — | — | — |
NCT03092674CT.gov Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT03383575CT.gov Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT03268954CT.gov Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | — | Completed | — | — | — |
NCT03047993CT.gov Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT03066648CT.gov Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | — | Completed | — | — | — |
NCT03113643CT.gov SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | — | Recruiting | — | — | — |
NCT03164057CT.gov A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03072043CT.gov Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | — | Completed | — | — | — |
NCT03146871CT.gov Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | — | Terminated | — | — | — |
NCT02995655CT.gov CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02942290CT.gov A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) | — | Active Not Recruiting | — | — | — |
NCT03030612CT.gov A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) | — | Completed | — | — | — |
NCT02807558CT.gov A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02750254CT.gov Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | — | Terminated | — | — | — |
NCT02775903CT.gov An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT02782468CT.gov A Study of Pevonedistat in Adult East Asian Participants | — | Completed | — | — | — |
NCT02719574CT.gov Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | — | Completed | — | — | — |
NCT02610777CT.gov An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | — | Completed | — | — | — |
NCT02750995CT.gov Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML | — | Completed | — | — | — |
NCT02543879CT.gov Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | — | Completed | — | — | — |
NCT02458235CT.gov Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation | — | Completed | — | — | — |
NCT02472691CT.gov Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT | — | Completed | — | — | — |
NCT02367456CT.gov A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients | — | Completed | — | — | — |
NCT02397720CT.gov Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02319369CT.gov Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | — | Terminated | — | — | — |
NCT02223052CT.gov Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | — | Completed | — | — | — |
NCT02129101CT.gov Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | — | Completed | — | — | — |
NCT01995578CT.gov Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse | — | Completed | — | — | — |
NCT01892371CT.gov Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01835587CT.gov Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). | — | Completed | — | — | — |
NCT01926587CT.gov Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | — | Completed | — | — | — |
NCT01869114CT.gov Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy | — | Completed | — | — | — |
NCT01908387CT.gov Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | — | Terminated | — | — | — |
NCT01700673CT.gov Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | — | Completed | — | — | — |
NCT01747499CT.gov Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | — | Terminated | — | — | — |
NCT01636609CT.gov Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | — | Terminated | — | — | — |
NCT01390311CT.gov Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant | — | Completed | — | — | — |
NCT01522976CT.gov Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT01556477CT.gov The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). | — | Unknown | — | — | — |
NCT01519011CT.gov Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | — | Completed | — | — | — |
NCT02124174CT.gov Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS | — | Unknown | — | — | — |
NCT01541280CT.gov VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01462578CT.gov Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) | — | Completed | — | — | — |
NCT01442714CT.gov Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS | — | Terminated | — | — | — |
NCT01488565CT.gov A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia | — | Completed | — | — | — |
NCT01290302CT.gov Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza | — | Completed | — | — | — |
NCT01168219CT.gov Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01110473CT.gov ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | — | Completed | — | — | — |
NCT01083706CT.gov Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | — | Completed | — | — | — |
NCT00911066CT.gov MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00923234CT.gov Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes | — | Terminated | — | — | — |
NCT00887068CT.gov Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | — | Completed | — | — | — |
NCT00652626CT.gov Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function | — | Completed | — | — | — |
NCT00795548CT.gov Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | — | Completed | — | — | — |
NCT00761722CT.gov Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma | — | Completed | — | — | — |
NCT00666497CT.gov Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | — | Terminated | — | — | — |
NCT00624936CT.gov Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT00528983CT.gov Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia | — | Completed | — | — | — |
NCT00741234CT.gov A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine | — | Completed | — | — | — |
NCT00392353CT.gov Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT00313586CT.gov Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00454480CT.gov Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT00446303CT.gov A Phase II Study of Maintenance With Azacitidine in MDS Patients | — | Terminated | — | — | — |
NCT00351975CT.gov Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | — | Completed | — | — | — |
NCT00569010CT.gov Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT00350818CT.gov Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) | — | Completed | — | — | — |
NCT00326170CT.gov Phase II 5-Azacytidine Plus VPA Plus ATRA | — | Completed | — | — | — |
NCT00101179CT.gov MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00004871CT.gov Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT00006019CT.gov Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | The First Affiliated Hospital of Soochow University | P3 | BB · 68 |
| Cyclophosphamide | Sawa Ito, MD | P4 | BB |
| Nivestim | City of Hope Medical Center | P4 | BB |
| Busulfanum | Sawa Ito, MD | P4 | BB |
| Daunomycin | OHSU Knight Cancer Institute | P3 | BB |
| Cytarabine | The First Affiliated Hospital of Soochow University | P4 | BB |
| Fludarabine | City of Hope Medical Center | P4 | BB |
| Idarubicin | OHSU Knight Cancer Institute | P4 | BB |
| Sitagliptin | Indiana University | P2 | BB |
+42 more in the Myelodysplastic Syndrome cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacitidine in Myelodysplastic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azacitidine-myelodysplastic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →